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ABSTRACT 
Non-alcoholic fatty liver disease (NAFLD) has been suggested to be well correlated with altered blood pressure. 
This study was conducted to determine the effects of symbiotic and vitamin E supplementation on blood pressure 
and inflammatory indices of patients with NAFLD. This randomized, double-blind, placebo-controlled trial was 
performed among 60 NAFLD patients aged 25 to 64 years old. Participants were randomly divided into four groups 
to receive a 400 IU alpha-tocopherol and 2 × 108 CFU/g symbiotic supplement for 8 weeks. The anthropometric 
parameters, systolic blood pressure (SBP) and diastolic blood pressure (DBP), serum malondialdehyde (MDA), 
nitric oxide (NO) and tumor necrosis factor α (TNFα) were assessed at baseline and after 8 weeks of intervention. 
After 8 weeks of intervention, combined symbiotic and alpha-tocopherol, symbiotic and alpha-tocopherol alone 
administration, compared with the placebo, resulted in significant decreases in SBP (-17.07±2.1,  
-16.07±3.56, -1.73±2.25 and -1.55±3.01 mmHg, P=0.01), serum MDA (-1.19±0.5, -0.12±0.65, 0.14 ± 0.64 and 
0.16±0.34 nmol/mL, P<0.001), serum TNFα (-15.62±13.93, -9.24±7.12, -11.44 ± 15.47 and 3.01±1.71 pg/ml, 
P<0.001) concentrations. A significant decrease in serum AST (-11.36±4.52, -7.43±8.58, -5.93±6.61 and 2.5±5.75 
μmol/L, P <0.001), ALT (-12.79±3.65, -3.66±6.81, -6.54±7.66 and 4.16±3.43 μmol/L, P <0.001) and ALP  
(-26.8±11.1, -4.56±9.22, -14.48±12.22 and 5.19±2.64 μmol/L, P <0.001) was seen. Variations in DBP and serum 
NO concentration were not significant. Alpha-tocopherol and symbiotic supplementation among patients with 
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NAFLD resulted in decreased SBP, serum MDA, TNFα levels and enzymes liver; however, they did not affect 
DBP and serum NO concentration. 
 
Keywords: symbiotic, alpha-tocopherol, blood pressure, nitric oxide, NAFLD 
 
 
 
INTRODUCTION 
NAFLD is one of the most common 
chronic liver diseases in the world today, oc-
curring when fat is deposited (steatosis) in the 
liver (Wong et al., 2014). The prevalence of 
NAFLD is reported to be 14–30 % of the gen-
eral population in different parts of the 
world(Adams and Angulo, 2006); this condi-
tion affects 21.5–31.5 % of adult’s population 
in Iran (Jamali et al., 2008). Various factors 
including obesity, insulin resistance, hypertri-
glyceridemia, hypertension, protein-calorie 
malnutrition, rapid weight loss, the use of 
medications such as glucocorticoids and met-
abolic factors are reported as contributors to 
the increased risk of NAFLD (Adams and 
Angulo, 2006). 
Not only insulin resistance and oxidative 
stress status are considered as roots of non-al-
coholic fatty liver disease, but also intestinal 
flora is responsible for NAFLD. Small intes-
tinal bacterial overgrowth (SIBO) is proposed 
to be responsible for the inflammation oc-
curred through the production of cytokine, yet 
the exact mechanism is still unknown 
(Medina et al., 2004). Some particular risk 
factors such as obesity, diabetes mellitus (in-
sulin resistance) and dyslipidemia can be 
strongly connected with NAFLD.  
Recent literature supports the role of a 
gut–liver interaction in the pathogenesis of 
portal hypertension as a novel therapeutic fo-
cus; the prevailing hypothesis is that bacterial 
translocation stimulates the release of pro-in-
flammatory cytokines and the activation of 
the vasodilator nitric oxide results in a more 
pronounced deterioration of the baseline hy-
perdynamic circulatory state (Chin-Dusting et 
al., 1997; Wiest et al., 1999). 
Subjects with NAFLD and elevated liver 
enzyme levels are at an increased risk of de-
veloping blood pressure and metabolic syn-
drome due to the oxidative stress status; in 
fact, decreased level of antioxidants in pa-
tients with NAFLD has effects on the 
measures of blood pressure. TNFα is also re-
sponsible for the pathogenesis of NAFLD via 
effecting on mitochondrial radical formation 
which might finally lead to cell death (Tilg 
and Diehl, 2000; Peralta and Rosello-Catafau, 
2004); on the other hand, intestinal flora has 
also a significant role in production of cyto-
kines (Solga and Diehl, 2003). 
Recently, it has been suggested that im-
moderate proliferation of pathogenic intesti-
nal bacteria is inhibited by probiotics; it has 
been well attested by animal and human re-
searches that probiotic bacteria could control 
blood pressure due to its antihypertensive ef-
fects (Reid et al., 2009). Some investigators 
have evidenced that probiotic bacteria may 
control blood pressure (Myhre et al., 2011; 
van Baarlen et al., 2011M; Ebel et al., 2014). 
This mechanism of action of probiotics is 
multifactorial, related to their impact on intes-
tinal microflora, cytokine production and 
maintenance of the epithelial barrier (Boiri-
vant and Strober, 2007). 
Further, antioxidant agents have been pro-
posed as a potentially effective treatment; vit-
amin E is a potent antioxidant compound that 
has been tested in pediatric NAFLD due to the 
absence of side effects. Conflicting results 
have been reported in clinical trials, among 
both children and adults (Lavine, 2000; 
Harrison et al., 2003; Vajro et al., 2004). 
Despite these findings, to the best of our 
knowledge, there are no reports regarding the 
favorable synergistic effects of the symbiotic 
and alpha-tocopherol supplementation on bi-
omarkers of inflammation, oxidative stress 
and blood pressure in NAFLD patients. We 
hypothesized that the combined supplementa-
tion with symbiotic and alpha-tocopherol 
might help NAFLD patients to control their 
blood pressure; the current trial was to assess 
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the effects of some species of probiotics along 
with alpha-tocopherol supplements on bi-
omarkers of inflammation, oxidative stress 
and blood pressure in NAFLD patients. 
 
MATERIALS  
Participants 
This randomized double-blind clinical 
trial was performed in Tehran, Iran, during 
2012 to 2013 among 60 NAFLD patients (48 
men and 12 women) aged 25 to 64 years old, 
who were recruited from Hazrat-e-Rasoul 
Medical Complex (Colorectal Research Cen-
ter) in Tehran, Iran.  
 
Ethics statements 
This study was conducted in accordance 
with the Declaration of Helsinki and informed 
consent was obtained from all participants. 
The research was approved by the ethics com-
mittee of IUMS and was recorded in the Ira-
nian website for registration of clinical trials 
(www.irct.ir: IRCT201111082709N22). 
 
Study design 
All eligible patients with NAFLD were re-
cruited (Figure 1). The diagnosis of NAFLD 
was based on hepatic ultrasonography (grade 
1 to 3), which was associated with the eleva-
tion of alanine aminotransferase (ALT) con-
centration (30 mg/dL) for 6 months before the 
study initiation and at the time of randomiza-
tion. The eligibility criteria included females 
and males with a body mass index (BMI) 
ranging from 25 to 35 kg/m2.
 
Figure 1: Flow diagram of patient recruitment and randomization process
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Exclusion criteria comprising any patho-
logic conditions affecting liver as viral hepa-
titis, alcohol consumption, hypothyroidism, 
Wilson disease, acute systemic disease, cystic 
fibrosis, coeliac disease and alpha-1-antitryp-
sin deficiency as well as a history of cancer, 
metabolic disorders, cardiovascular disease, 
autoimmune diseases and drug or alcohol 
abuse. Diabetes mellitus, pregnancy, lacta-
tion, menstruation at the time of blood sam-
pling, infectious diseases during the study,  
using non-steroidal anti-inflammatory drugs, 
antibiotics, and probiotics and food supple-
ments prior to the enrolment of  the study 
were also considered as exclusion criteria. 
Physical examinations, medical history, 
diet and physical activity level of each patient 
were assessed at the beginning of the study. 
Subjects were asked not to consume any pro-
biotic containing food, yogurt, or its products 
during an initial 2 week run-in period before 
the study. They were also asked not to con-
sume other probiotic products during the in-
tervention. At the end of the run-in period, el-
igible patients were randomly assigned to one 
of the named groups. Symbiotic Group 
(n=15) who consumed symbiotic and alpha-
tocopherol-like placebo capsule, alpha-to-
copherol group (n=15) who received alpha-
tocopherol and symbiotic-like placebo, sym-
biotic + alpha-tocopherol group (n=15) who 
consumed symbiotic and alpha-tocopherol 
supplementation and the final 15 patients 
were given symbiotic-like placebo and an al-
pha-tocopherol-like placebo supplementation 
as control group. 
 
Intervention 
Each symbiotic capsule [Protexin; Probi-
otics International Ltd., Lopen Head, Somer-
set, United Kingdom] contained Lactobacil-
lus casei, Lactobacillus rhamnosus, Streto-
coccus thermophilus, Bifidobacterium breve, 
Lactobacillus acidophilus, Bifidobacterium 
longum, Lactobacillus bulgaricus and prebi-
otic (fructooligosaccharide). The concentra-
tion of each probiotic strain was 2 × 108 
CFU/g per capsule. Patients were asked to 
consume 2 symbiotic capsules per day (each 
capsule contained 1 g) orally after the main 
meal. Two identical-appearing placebo cap-
sules [corn starch, Zahravi Pharmaceutical 
Co, Tabriz, Iran] were taken daily by partici-
pants assigned to either the placebo or the al-
pha-tocopherol group. Justification for choos-
ing this dosage was based on the earlier study 
(Aller et al., 2011). Alpha-tocopherol [RRR-
α-tocopherol, Zahravi Pharmaceutical Co, 
Tabriz, Iran] at a daily dosage of 400 IU and 
similar appearing placebo were administered 
orally. This chosen dose of alpha-tocopherol 
was similar to previous study in NAFLD pa-
tients (Chalasani et al., 2012). 
Randomization was carried out according 
to Balanced Block Randomization procedure 
while participants, nutrition specialists, and 
outcome assessors were all blinded to the in-
terventions into which the individuals were 
allocated. This study was granted by Iran Na-
tional Science Foundation. 
 
Treatment adherence 
Compliance was monitored by phone 
calls weekly and verified using capsule counts 
(number of capsules left in the capsule bottle 
at the end of the study). 
 
Assessment of anthropometric measures 
Weight (Seca, Hamburg, Germany) was 
measured at study baseline and after 8 weeks 
of intervention. Height was measured using a 
non-stretched tape measure (Seca, Hamburg, 
Germany). BMI was calculated using the 
height and weight measurements (weight in 
kg/[height in meters]2). 
 
Assessment of outcomes 
The primary objective was a reduction in 
SBP and DBP in NAFLD patient with daily 
alpha-tocopherol and symbiotic supplementa-
tion; secondary objectives were changes in se-
rum nitric oxide, MDA and serum TNFα. 
Levels of serum TNFα were measured using 
enzyme linked immunosorbent assay kits 
(eBioscience, USA). Plasma MDA levels 
were determined by thiobarbituric acid reac-
tive substance spectrophotometric test 
(Janero, 1990). Plasma nitrite/nitrate, taken as 
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an index of nitric oxide (NO) concentrations, 
was determined using the Giess method 
which was modified by Tatsch et al. (2011). 
 
Randomization 
Randomization assignment was per-
formed using computer-generated random 
numbers. Randomization and allocation were 
blinded to the researchers and participants un-
til the final analyses were completed. The ran-
domized allocation sequence as well as enrol-
ling participants and allocating them to inter-
ventions were conducted by a trained staff at 
the department of nutrition. 
 
Statistical analysis 
To examine the normal distribution of 
variables, we used Kolmogorov–Smirnov 
test. The analyses were conducted based on 
intention-to-treat (ITT) approach. One-way 
analysis of variance (ANOVA) was used to 
detect differences in general characteristics, 
dietary intakes, chemical biomarkers and 
blood pressure at the study initiation between 
the four groups. A Pearson χ2 test was used 
for comparison of categorical variables. Re-
peated measure ANOVA was used to deter-
mine the effects of symbiotic plus alpha-to-
copherol administration on blood pressure 
and the used biomarkers, we adjusted the 
analysis for biochemical parameters, age and 
BMI, to assess their confounding effects. P 
values less than 0.05 were considered as sta-
tistically significant. All statistical analyses 
were done using the Statistical Package for 
Social Science version 17 (SPSS Inc., Chi-
cago, Ill., USA). 
 
RESULTS 
65 NAFLD patients were recruited in the 
study at baseline; however, 2 subjects were 
excluded as one of them was not a local resi-
dent (n = 1) and the other had a sudden heart 
attack during the study (n = 1); furthermore, 
in the symbiotic group, 2 subjects [death (1 = 
3)], s (n = 1)] were excluded from the alpha-
tocopherol group, due to personal reason and 
death. Moreover, 2 persons [death (n = 1) and 
withdrawal due to personal reasons (n = 1)] 
were excluded from the placebo group. Fi-
nally, 60 participants [symbiotic (n = 15), al-
pha-tocopherol (n = 15), symbiotic plus al-
pha-tocopherol (n = 15) and placebo (n = 15)] 
completed the trial. However, as the analysis 
was performed based on intention-to-treat 
principle, all 60 patients (15 in each group) 
were included in the final analysis. No side 
effects were recorded following the admin-
istration of symbiotic, alpha-tocopherol, and 
joint symbiotic and alpha-tocopherol supple-
ments in patients with NAFLD throughout the 
study. 
There were no initial differences in the 
mean measures of age (44 ± 20 y, P = 0.09), 
height, body weight, SBP, DBP and BMI be-
tween all the groups. Table 1 summarizes the 
selected data of patients at the beginning and 
the end of the study.  
In addition, mean values of height, weight 
and BMI were not statistically different be-
tween the four groups after the treatment pe-
riod. 
According to the 3-day dietary records 
that were obtained throughout the interven-
tion, no statistically significant differences 
were seen between the four groups in terms of 
macro- and micro-nutrient intakes (Table 2). 
Joint supplementation with symbiotic and 
alpha-tocopherol had no significant effects on 
DBP and serum NO levels. After 8 weeks of 
intervention, all three groups of alpha-tocoph-
erol only, individual symbiotic, and combined 
symbiotic and alpha-tocopherol experienced a 
significant improvements in SBP compared 
with the placebo group (P=0.01); however, 
improvements were much greater in the indi-
vidual symbiotic (-16.07±3.56 mmHg) and 
combined symbiotic and alpha-tocopherol  
(-17.07±2.1 mmHg) groups compared with 
alpha-tocopherol group alone (-1.73±2.25 
mmHg) (Table 1).
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Table 1: Baseline, end and change values of anthropometric indicators and blood pressure of study 
participants 
Characteristic Symbiotic 
(n=15) 
Alpha- 
tocopherol 
(n=15) 
Symbiotic +  
Alpha-toco- 
phero  (n=15) 
Placebo 
(n=15) 
P a 
Height (cm)†      
Baseline  172.66±10.97* 171.73±6.48 168.6±9.33 172.93±8.27 0.52 
Weight (kg)†      
Baseline   80.73±9.12 84.86±12.71 79.8±10.05 83.46±10.25 0.53 
End  80.33±9.17 84.66±12.71 79.6±10.15 86.46±7.33 0.51 
Change  -0.4±0.31 -0.2±0.18 -0.2±0.16 3±1.8 0.21 
P b 0.11 0.38 0.42 0.61  
WC (cm)†      
Baseline  93.6±6.52 91.73±9.91 94.93±8.33 96.46±7.33 0.438 
End  93.86±6.65 91.63±10.02 94.86±8.15 96.53±7.5 0.427 
Change  0.26±0.3 -0.1±0.31 -0.07±0.1 0.07±0.13 0.2 
P b 0.34 0.45 0.43 0.61  
BMI (kg/m2)‡      
Baseline  27.28±2.21 28.77±4.08 28.05±2.52 27.84±1.96 0.72 
End  27.14±2.26 28.7±4.06 27.98±2.65 27.8±1.98 0.68 
Change  -0.14±0.2 -0.07±0.12 -0.07±0.08 -0.04±0.1 0.54 
P b  0.21 0.57 0.95 0.56  
SBP      
Baseline  139.33±7.3 131.06±8.25 138.6±4.71 136.6±6.31 0.31 
End  123.26±7.49 129.33±5.47 121.53±3.5 135.06±4.92 0.001 
Change  -16.07±3.56 -1.73±2.25 -17.07±2.1 -1.55±3.01 0.01 
P b  0.001 0.04 0.001 0.2  
DBP       
Baseline  81.66±3.61 83±5.9 80.8±5.85 81.45±4.56 0.21 
End  81.13±5.79 82.4±5.48 81.02±3.5 80.86±1.3 0.6 
Change  -0.53±0.12 -0.6±0.17 -0.22±0.2 -0.59±0.1 0.31 
P b  0.4 0.4 0.7 0.07  
Alpha-tocopherol group received 400 IU alpha-tocopherol per day plus a daily placebo for symbiotic, symbiotic group received 2 
× 108 CFU/g symbiotic plus a daily placebo for alpha-tocopherol, and symbiotic plus alpha-tocopherol group received symbiotic 
(2 × 108 CFU/g) plus 400 IU alpha-tocopherol per day. 
WC Waist circumference, BMI body mass index, SBP systolic blood pressure; DBP diastolic blood pressure 
a Obtained from ANOVA 
b Obtained from Kruskal Wallis test 
 
 
A significant decrease in serum MDA was 
shown in all intervention groups (alpha-to-
copherol: 0.14±0.64; symbiotic: -0.12±0.65; 
combined group: -1.19±0.5 and placebo: 
0.16±0.34 nmol/mL, P<0.001). Reduction in 
the levels of TNFα among individuals taking 
co-supplements of symbiotic and alpha-to-
copherol, was greater in comparison to the 
other groups (alpha-tocopherol: -11.44± 
15.47; symbiotic: -9.24±7.12; combined 
group: -15.62±13.93 and placebo: 3.01±1.71 
pg/mL, P=0.001). 
Furthermore, a significant decrease in se-
rum AST level was seen among both individ-
ual and combined intervention with symbiotic 
and alpha-tocopherol groups (combined 
group: -11.36±4.52; alpha-tocopherol: -5.93± 
6.61; symbiotic: -7.43±8.58; and placebo: 
2.5±5.75μmol/L, respectively, P<0.001), 
ALT (combined group: -12.79±3.65; alpha-
tocopherol: -3.66±6.81;  symbiotic: -6.54± 
7.66; and placebo: 4.16±3.43 μmol/L, respec-
tively, P<0.001) and ALP (combined group:  
-26.8±11.1; alpha-tocopherol: -4.56±9.22; 
symbiotic: -14.48±12.22; and placebo: 
5.19±2.64 μmol/L, respectively, P<0.001) 
(Table 3). 
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Table 2: Dietary intakes of study participants throughout the study 
Variables  Symbiotic 
(n=15) 
Alpha- tocopherol 
(n=15) 
Symbiotic +   
Alpha-tocopherol 
(n=15) 
Placebo 
(n=15) 
P a 
Calorie 1940.3571±149.72981 1955.1333±213.95556 1945.1333±162.63318 1891.0667±184.17207 0.76 
Protein 57.6107±10.97471 54.9627±7.80618 52.2153±7.20433 52.3400±11.53624 0.38 
Carbohy-
drate 
245.8071±38.98014 243.8533±49.65163 238.1733±47.28759 236.5200±45.98121 0.93 
Fat 83.9657±10.21192 87.8360±11.75027 89.3540±11.87602 85.1940±14.18442 0.61 
Cholesterol 179.8979±114.38910 165.2173±63.62592 189.9553±85.26248 166.8887±100.01035 0.86 
SFA 20.5757±6.35236 18.9960±3.59449 18.7987±5.25333 18.1389±5.61779 0.65 
PUFA 24.0829±5.25011 25.5720±6.64536 26.8307±4.55500 24.1327±5.01007 0.46 
MUFA 34.4879±4.06871 37.1860±7.29581 38.5520±6.12216 37.0287±6.74004 0.37 
Na 840.2857±271.26842 856.5720±343.41864 747.7200±434.01224 813.3000±461.29867 0.87 
K 1949.8571±565.27092 2052.8000±586.88040 1613.8000±286.44077 1796.4000±500.60104 0.09 
Mg 232.1500±42.29160 229.8867±31.43471 197.3133±35.92915 193.8733±40.65047 0.008 
Ca 548.4214±193.82611 495.3467±163.85079 431.2667±101.77142 409.0267±105.02815 0.05 
P 905.1857±190.05972 914.3467±97.69873 802.8533±88.10760 817.0000±124.98897 0.04 
Dietary fiber 14.0343±3.26031 14.0261±2.75041 13.2667±2.11703 13.0901±3.62357 0.74 
Vitamin D 9.9019±24.11390 0.5003±0.29340 0.5478±0.37256 0.4912±0.42154 0.08 
Data are means ± SDs 
Alpha-tocopherol group received 400 IU alpha-tocopherol per day plus a daily placebo for symbiotic, symbiotic group received 2 
× 108 CFU/g symbiotic plus a daily placebo for alpha-tocopherol, and symbiotic plus alpha-tocopherol group received symbiotic 
(2 × 108 CFU/g) plus 400 IU alpha-tocopherol per day. 
SFA= saturated fatty acids; PUFA= poly unsaturated fatty acids; MUFA=mono unsaturated fatty acids; NA= natrium; K= Kalium; 
Mg= Magnesium; Ca= Calcium; P= Phosphorus  
a Obtained from ANOVA test 
 
 
When the analyses were adjusted for base-
line values including biochemical parameters, 
age and BMI, significant changes in our find-
ings were observed except for NO (P = 0.82) 
and DBP (P = 0.82) levels (Table 4). 
 
DISCUSSION 
This study demonstrated that administra-
tion of symbiotic and alpha-tocopherol sup-
plements for 8 weeks among patients with 
NAFLD had beneficial effects on SBP, liver 
enzymes,  serum TNFα and MDA levels com-
pared with the control group, while they did 
not affect DBP and serum NO levels. To the 
best of our knowledge, this is the first study 
evaluating the favorable synergistic effects of 
symbiotic and alpha-tocopherol supplementa-
tion on blood pressure and biomarkers of in-
flammation and oxidative stress among pa-
tients with NAFLD.  
Our study revealed that consumption of 2 
× 108 CFU/g symbiotic and 400 IU of alpha-
tocopherol for 8 weeks among patients with 
NAFLD compared with the placebo group led 
to significant reductions in SBP. 
In line with our findings, in a study by 
Yamamoto et al.(Yamamoto et al., 1994)oral 
administration of Lactobacillus acidophilus 
yoghurt in spontaneously hypertensive rats 
(SHR) has shown that milk fermented with L. 
heveticus and casein hydrolysates, which 
were produced by this organisms, have anti-
hypertensive activity. Cell wall polysaccha-
ride-glycoprotein complexes of L. casei have
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Table 3: Baseline, end and change values of serum liver enzymes and some measured inflammatory 
factors of study participants 
Characteristic Symbiotic 
(n=15) 
Alpha-tocopherol 
(n=15) 
Symbiotic +  
Alpha-tocopherol 
(n=15) 
Placebo 
(n=15) 
P a 
ALT (IU/L)      
Baseline  38.14±8.72* 35.73±5.83 38.14±7.77 33.88±4.49 0.27 
End  31.59±9.42 32.06±7.39 25.35±7.98 38.05±6.54 0.001 
Change  -6.54±7.66 -3.66±6.81 -12.79±3.65 4.16±3.43 <0.001 
P b 0.005 0.06 <0.001 0.06  
ALP (IU/L)      
Baseline  148.63±26.92 158.1±36.23 147.6±14.95 150.85±21.97 0.81 
End  133.79±20.88 153.53±38.16 120.79±15.35 156.04±22.52 0.003 
Change  -14.48±12.22 -4.56±9.22 -26.8±11.1 5.19±2.64 <0.001 
P b  0.001 0.03 0.001 0.07  
AST (IU/L)      
Baseline  37.95±15.34 30.53±8.01 36.84±7.3 32.04±7.06 0.048 
End  30.52±13.4 24.6±6.64 25.47±5.99 34.54±6.8 0.004 
Change  -7.43±8.58 -5.93±6.61 -11.36±4.52 2.5±5.75 <0.001 
P b  0.001 0.004 0.001 0.112  
NO (µmol/L)      
Baseline  24±12 31.06±12.4 24.87±13 28.4±14 0.4 
End  26.18±14 31.79±12 25±12 29.12±13 0.37 
Change  2.18±3.8 0.73±2.1 0.13±1.5 0.7±1.2 0.21 
P b  0.4 0.7 0.8 0.2  
MDA (µmol/mL)      
Baseline  2.2±0.68 2.24±0.54 2.28±0.53 2.18±0.48 0.9 
End  2.08±0.57 2.09±0.86 1.09±0.4 2.34±0.57 <0.001 
Change  -0.12±0.65 -0.14±0.64 -1.19±0.5 0.16±0.34 
 
<0.001 
P b  0.62 0.34 0.001 0.07  
TNFα ( pg/ml )      
Baseline  40.28±15.28 43.72±27.14 43.86±14.17 39.06±8.53 0.2 
End  31.04±16.33 32.28±25.68 28.23±7.68 42.08±9.05 0.001 
Change  -9.24±7.12 -11.44±15.47 -15.63±13.93 3.01±1.71 <0.001 
P b  0.001 0.001 0.001 0.09  
Alpha-tocopherol group received 400 IU alpha-tocopherol per day plus a daily placebo for symbiotic , symbiotic group received 2 
× 108 CFU/g symbiotic plus a daily placebo for alpha-tocopherol, and symbiotic plus alpha-tocopherol group received symbiotic 
(2 × 108 CFU/g) plus 400 IU alpha-tocopherol per day. 
ALT alanine aminotransferase; AST aspartate aminotransferase; ALP alkaline phosphatase; NO nitric oxide; MDA malondialde-
hyde ; TNFα tumor necrosis factor α.  
a Obtained from ANOVA. 
b Obtained from Kruskal Wallis test. 
 
 
also been reported to have antihypertensive 
activity in SHR and hypertensive rats 
(Sawada et al., 1990; Furushiro et al., 1993), 
it has been suggested that probiotic therapy 
may decrease blood pressure in cirrhosis via 
reducing intestinal permeability and bacterial 
translocation, decreasing the exposure of the 
immune system to intestinal bacteria and bac-
terial products and thereby reducing the in-
flammatory cytokines. Endotoxin is hypothe-
sized to be originated from the intestinal tract 
as a result of increased gut permeability and 
bacterial translocation; in the study of Tandon 
et al. (2009), there was a trend in the reduction 
of plasma endotoxin levels which was re-
sulted by probiotic therapy, suggesting that 
probiotics would be effective in enhancing the 
gut barrier function, but the magnitude of 
change might have not been detectable by the 
intestinal permeability technique utilization. 
Data on diastolic blood pressure needs to 
be interpreted with caution, and future studies 
with larger sample size would hopefully pro-
vide valuable information concerning this 
topic.
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Table 4: Adjusted changes in biochemical measurement and blood pressure in NAFLD patients that 
received symbiotic plus alpha-tocopherol, symbiotic and alpha-tocopherol supplements or placebo 
 Symbiotic 
(n=15) 
Alpha- 
tocopherol 
(n=15) 
Symbiotic + 
Alpha-tocopherol 
(n=15) 
Placebo 
(n=15) 
Pa 
ALP (IU/L) -15.24±2.3 -3.7±2.52 -27.11±2.46 5.04±2.47 <0.001 
AST (IU/L) -6.34±1.5 -7.23±1.5 -10.47±1.4 1.81±1.42 <0.001 
ALT (IU/L) -6.44±1.49 -3.69±1.5 -12.43±1.47 3.72±1.5 <0.001 
SBP (mm/Hg) -3.55±7.43 -0.63±0.76 -6.89±0.73 1.68±0.74 <0.001 
DBP (mm/Hg) -0.49±0.71 -0.35±0.73 -0.89±0.7 0.34±0.71 0.65 
TNFα (pg/ml ) -9.18±2.63 -11.66±2.7 -15.01±2.6 2.57±2.62 <0.001 
NO (µmol/L) 1.18±0.8 0.69±0.4 0.5±0.3 0.1±0.01 0.2 
MDA (nmol/ml) -0.15±0.13 -0.12±0.14 -1.16±0.13 0.14±0.13 <0.001 
Alpha-tocopherol group received 400 IU alpha-tocopherol per day plus a daily placebo for symbiotic, symbiotic group received 2 
× 108 CFU/g symbiotic plus a daily placebo for alpha-tocopherol, and symbiotic plus alpha-tocopherol group received symbiotic 
(2 × 108 CFU/g) plus 400 IU alpha-tocopherol per day. 
ALP alkaline phosphatase; AST aspartate aminotransferase; ALT alanine aminotransferase; SBP systolic blood pressure; DBP 
diastolic blood pressure; TNFα tumor necrosis factor α; NO nitric oxide; MDA malondialdehyde 
All values are means ± SEs. Values are adjusted for baseline values, age and baseline BMI. 
 
 
Findings from this study have shown that 
consumption of the symbiotic and alpha-to-
copherol for 8 weeks among NAFLD patients 
significantly reduced serum TNFα compared 
with the placebo. 
The beneficial effects of some probiotic 
species on serum TNFα concentration among 
patients with NAFLD have previously been 
evaluated (Aller et al., 2011; Vajro et al., 
2011; Malaguarnera et al., 2012). Supporting 
our study, a study by Malaguarnera et al. 
(2012) reported significant decreases in se-
rum TNFα levels after 24 weeks of interven-
tion with Bifidobacterium longum and fructo-
oligosaccharides among patients with non-al-
coholic steatohepatitis. This protective effect 
is as a result of reduced hepatic exposure to 
intestinal products, such as lipopolysaccha-
rides (LPS), which induced the release of 
TNFα from hepatic macrophage. TNFα is a 
cytokine that promotes cell death in the liver 
and increases inflammation and thus blood 
pressure (Solga and Diehl, 2003). 
It is logical to assume that similar effects 
of intestinal flora and NAFLD also exist, 
since TNFα is the key mediator of inflamma-
tion and so hypertension in this disease. Cur-
rently, there are two mechanisms in which in-
testinal flora may increase the hepatic oxida-
tive stress and thus the blood pressure; the 
first is the increased endogenous ethanol pro-
duction, and the second is the direct activation 
of inflammatory cytokines in luminal epithe-
lial cells, non-parenchymal liver cells (macro-
phages) or both of them via releasing LPS, 
which may activate the production of TNFα 
in Kupffer cells and thus induce hepatic in-
flammation, oxidative stress and high blood 
pressure (Aqel and DiBaise, 2015).  
High amounts of bacterial DNA and their 
derivatives induce the production of TNFα, 
IL-2, IL-6, IL-12 (Frances et al., 2004; 
Frances et al., 2005). In the liver, the exten-
sive attachment of LPS to CD4/TLR4 induces 
high amounts of LPS-binding protein 
(Albillos et al., 2003). Inefficient local im-
munity was demonstrated in liver disease, 
particularly in patients with cirrhosis; the po-
tent mechanism is a depression in the activity 
of kupffer cells and the reticular endothelium 
system which plays a significant role in the 
defense against infected bacteria (Rimola et 
al., 1984). Our findings differ from previous 
study due to TNFα levels; precisely, in the 
study by Tandon et al. (2009) small increase 
observed in serum TNFα, was an unexpected 
finding after the probiotic therapy which 
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could be anticipated to reduce the levels of 
pro-inflammatory mediators; although there 
were no significant adverse events of probi-
otic administration in patients with liver dis-
ease either in the current study or in previous 
ones (Rayes et al., 2002, 2005; Lata et al., 
2007) there is a probability that an increase in 
the production of TNFα may represent harm-
ful effects. There are two relevant subjects in 
this context, different types of probiotic spe-
cies used in these studies and small sample 
size.  
In line with Loguercio et al. (2005), the 
current study revealed that simultaneous sup-
plementation of 400 IU alpha-tocopherol and 
symbiotic had synergistic effect on the reduc-
tion of serum MDA in NAFLD patients; the 
mentioned study demonstrated that supple-
mentation of probiotic VSL#3 in NAFLD pa-
tients could significantly improve plasma lev-
els of MDA; another study has demonstrated 
that supplementation with Lactobacillus casei 
in the hyperlipidemic rats, decreased the lev-
els of MDA (Zhang et al., 2010). 
Ejtehad et al. (2012) showed that con-
sumption of 300 g/d of probiotic yogurt con-
taining Lactobacillus acidophilus La5 and 
Bifidobacterium lactis Bb12 could signifi-
cantly decrease serum MDA concentration in 
type 2 diabetic patients; moreover, Daga et al. 
(2003) found an inverse association between 
400 IU/d vitamin E supplementation and se-
rum MDA among COPD patients. 
Oxidative stress is now believed to be an 
important factor in the development of hyper-
tension in non-alcoholic fatty liver disease; 
increased blood pressure is found to be asso-
ciated with NAFLD in patients with increased 
alanine transaminase concentrations (Lau et 
al., 2010). Although, the mechanism explain-
ing the association between NAFLD and in-
creased blood pressure is still unclear, it has 
recently been demonstrated that there is a 
general thickening of the left ventricular wall 
and lipid peroxidation in NAFLD (Cassidy et 
al., 2015); increased wall thickness due to the 
oxidative stress is associated with reduced 
longitudinal fiber shortening which is indica-
tive for left ventricular hypertrophy 
(Hollingsworth et al., 2012); this hypertrophy 
of the cardiac wall may also lead to the in-
creased ventricular strain that is seen in 
NAFLD, which both finally affect the endo-
cardium and entire wall as a result of the al-
tered geometry (reduced radius). 
This study assessed the supplementation 
of both symbiotic and alpha-tocopherol on se-
rum NO concentration in people with 
NAFLD; although the plasma NO levels were 
increased in all intervention groups, the 
changes were not significant. The beneficial 
effects of vitamin E supplementation on se-
rum NO and so blood pressure among patients 
with metabolic syndrome have been previ-
ously evaluated (Vivekananthan et al., 2003; 
Rodrigo et al., 2008). 
Vasodilation in response to the increased 
flow is a function of the normal endothelium 
through the secretion of NO; loss of normal 
endothelial function results in impaired vaso-
dilation and increased blood pressure and may 
be a common pathway to hypertension (Giles 
et al., 2012). Antioxidants such as vitamin E 
have beneficial effects on controlling hyper-
tension and reducing oxidative damage which 
result in a reduction in blood pressure levels 
(Baradaran et al., 2014). 
NO plays an important role in regulating 
systemic vascular resistance, arterial relaxa-
tion, and dispensability; collectively, these 
actions reduce cardiac hemodynamic load, 
which thereby reduce myocardial hypertro-
phy and left ventricular dysfunction and fi-
nally protect target organs (Raij, 2001; 
Wilkinson et al., 2004). Thus, NO plays a ma-
jor role in maintaining and regulating blood 
pressure. 
The strengths of the current study were the 
double blinding methods without any dropout 
rates. This study had some limitations, as well 
first of all, duration of intervention was rela-
tively short. Moreover, we did not evaluate 
the effects of symbiotic and vitamin E supple-
mentation on other factors related to blood 
pressure including rennin and angiotensin 
levels. 
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In addition, because of the budget limita-
tions, we could not assess other biomarkers of 
systemic inflammation including interleukin 
1(IL-1) and IL-6 as well as the biomarkers of 
oxidative stress such as catalase and superox-
ide dismutase in NAFLD patients. Future 
studies with crossover design, longer duration 
of intervention and larger sample size are 
needed to confirm the validity of our findings. 
 
CONCLUSION 
Overall, administration of 400 IU alpha-
tocopherol and symbiotic supplements con-
taining Lactobacillus casei, Lactobacillus 
rhamnosus, Stretococcus thermophilus, 
Bifidobacterium breve, Lactobacillus aci-
dophilus, Bifidobacterium longum, and Lac-
tobacillus bulgaricus for 8 weeks among pa-
tients with NAFLD had beneficial effects on 
systolic SBP, MDA and TNFα but did not af-
fect DBP and serum NO levels compared with 
the control group. Findings of the current 
study suggest that simultaneous supplementa-
tion of vitamin E and symbiotic may confer 
advantageous therapeutic outcomes for pa-
tients with NAFLD. 
 
 Compliance with ethical standards 
Funding: This study was funded by Iran 
national science foundation (grant number: 
90005246). 
Conflict of interest: The authors declare 
that they have no conflict of interest. 
Ethical approval: All procedures per-
formed in studies involving human partici-
pants were in accordance with the ethical 
standards of the institutional and/or national 
research committee and with the 1964 Hel-
sinki declaration and its later amendments or 
comparable ethical standards. 
Informed consent: Informed consent was 
obtained from all individual participants in-
cluded in the study. 
 
Acknowledgements 
The authors thank the participants in the 
study for their important contributions. 
 
REFERENCES  
Adams LA, Angulo P. Treatment of non-alcoholic fatty 
liver disease. Postgrad Med J. 2006;82(967):315-22. 
Albillos A, de la Hera A, Gonzalez M, Moya JL, 
Calleja JL, Monserrat J, et al. Increased lipopolysac-
charide binding protein in cirrhotic patients with 
marked immune and hemodynamic derangement. 
Hepatology (Baltimore, Md). 2003;37:208-17. 
Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sa-
grado M, Primo D, et al. Effect of a probiotic on liver 
aminotransferases in nonalcoholic fatty liver disease 
patients: a double blind randomized clinical trial. Eur 
Rev Med Pharmacol Sci. 2011;15:1090-5. 
Aqel B, DiBaise JK. Role of the gut microbiome in 
nonalcoholic fatty liver disease. Nutr Clin Pract. 
2015;30:780-6. 
Baradaran A, Nasri H, Rafieian-Kopaei M. Oxidative 
stress and hypertension: Possibility of hypertension 
therapy with antioxidants. J Res Med Sci. 2014;19: 
358-67. 
Boirivant M, Strober W. The mechanism of action of 
probiotics. Curr Opin Gastroenterol. 2007;23:679-92. 
Cassidy S, Hallsworth K, Thoma C, MacGowan GA, 
Hollingsworth KG, Day CP, et al. Cardiac structure 
and function are altered in type 2 diabetes and non-al-
coholic fatty liver disease and associate with glycemic 
control. Cardiovasc Diabetol. 2015;14:23. 
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt 
EM, Cusi K, et al. The diagnosis and management of 
non-alcoholic fatty liver disease: practice guideline by 
the American Gastroenterological Association, Ameri-
can Association for the Study of Liver Diseases, and 
American College of Gastroenterology. Gastroenterol-
ogy. 2012;142:1592-609. 
Chin-Dusting JP, Rasaratnam B, Jennings GL, Dudley 
FJ. Effect of fluoroquinolone on the enhanced nitric 
oxide-induced peripheral vasodilation seen in cirrho-
sis. Ann Intern Med. 1997;127:985-8. 
Daga MK, Chhabra R, Sharma B, Mishra TK. Effects 
of exogenous vitamin E supplementation on the levels 
of oxidants and antioxidants in chronic obstructive pul-
monary disease. J Biosci. 2003;28:7-11. 
Ebel B, Lemetais G, Beney L, Cachon R, Sokol H, 
Langella P, et al. Impact of probiotics on risk factors 
for cardiovascular diseases. A review. Crit Rev Food 
Sci Nutr. 2014;54:175-89. 
EXCLI Journal 2017;16:278-290 – ISSN 1611-2156 
Received: December 18, 2016, accepted: February 11, 2017, published: March 20, 2017 
 
 
289 
Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar 
M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt 
improves antioxidant status in type 2 diabetic patients. 
Nutrition. 2012;28:539-43. 
Frances R, Munoz C, Zapater P, Uceda F, Gascon I, 
Pascual S, et al. Bacterial DNA activates cell mediated 
immune response and nitric oxide overproduction in 
peritoneal macrophages from patients with cirrhosis 
and ascites. Gut. 2004;53:860-4. 
Frances R, Rodriguez E, Munoz C, Zapater P, De la 
ML, Ndongo M, et al. Intracellular cytokine expression 
in peritoneal monocyte/macrophages obtained from 
patients with cirrhosis and presence of bacterial DNA. 
Eur J Gastroenterol Hepatol. 2005;17:45-51. 
Furushiro M, Hashimoto S, Hamura M, Yokokura T. 
Mechanism for the antihypertensive effect of a poly-
saccharide-glycopeptide complex from Lactobacillus 
casei in spontaneously hypertensive rats (SHR). Biosci 
Biotechnol Biochem. 1993;57:978-81. 
Giles TD, Sander GE, Nossaman BD, Kadowitz PJ. 
Impaired vasodilation in the pathogenesis of hyperten-
sion: focus on nitric oxide, endothelial-derived hy-
perpolarizing factors, and prostaglandins. J Clin Hy-
pertens. 2012;14:198-205. 
Harrison SA, Torgerson S, Hayashi P, Ward J, Schen-
ker S. Vitamin E and vitamin C treatment improves fi-
brosis in patients with nonalcoholic steatohepatitis. Am 
J Gastroenterol. 2003;98:2485-90. 
Hollingsworth KG, Blamire AM, Keavney BD, Mac-
gowan GA. Left ventricular torsion, energetics, and di-
astolic function in normal human aging. Am J Physiol 
Heart Circ Physiol. 2012;302:885-92. 
Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, 
Bahram Kalhori A, et al. Persistent alanine aminotrans-
ferase elevation among the general Iranian population: 
prevalence and causes. World J Gastroenterol. 2008; 
14:2867-71. 
Janero DR. Malondialdehyde and thiobarbituric acid-
reactivity as diagnostic indices of lipid peroxidation 
and peroxidative tissue injury. Free Radic Biol Med. 
1990;9:515-40. 
Lata J, Novotny I, Pribramska V, Jurankova J, Fric P, 
Kroupa R, et al. The effect of probiotics on gut flora, 
level of endotoxin and Child-Pugh score in cirrhotic 
patients: results of a double-blind randomized study. 
Eur J Gastroenterol Hepatol. 2007;19:1111-3. 
Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschof-
ski H, Nauck M, et al. The association between fatty 
liver disease and blood pressure in a population-based 
prospective longitudinal study. J Hypertens. 2010;28: 
1829-35. 
Lavine JE. Vitamin E treatment of nonalcoholic stea-
tohepatitis in children: a pilot study. J Pediatr. 2000; 
136:734-8. 
Loguercio C, Federico A, Tuccillo C, Terracciano F, 
D'Auria MV, De Simone C, et al. Beneficial effects of 
a probiotic VSL#3 on parameters of liver dysfunction 
in chronic liver diseases. J Clin Gastroenterol. 2005; 
39:540-3. 
Malaguarnera M, Vacante M, Antic T, Giordano M, 
Chisari G, Acquaviva R, et al. Bifidobacterium longum 
with fructo-oligosaccharides in patients with non alco-
holic steatohepatitis. Dig Dis Sci. 2012;57:545-53. 
Medina J, Fernandez-Salazar LI, Garcia-Buey L, 
Moreno-Otero R. Approach to the pathogenesis and 
treatment of nonalcoholic steatohepatitis. Diabetes 
Care. 2004;27:2057-66. 
Myhre R, Brantsaeter AL, Myking S, Gjessing HK, 
Sengpiel V, Meltzer HM, et al. Intake of probiotic food 
and risk of spontaneous preterm delivery. Am J Clin 
Nutr. 2011;93:151-7. 
Peralta C, Rosello-Catafau J. The future of fatty livers. 
J Hepatol. 2004;41:149-51. 
Raij L. Hypertension and cardiovascular risk factors: 
role of the angiotensin II-nitric oxide interaction. Hy-
pertension. 2001;37:767-73. 
Rayes N, Seehofer D, Hansen S, Boucsein K, Muller 
AR, Serke S, et al. Early enteral supply of lactobacillus 
and fiber versus selective bowel decontamination: a 
controlled trial in liver transplant recipients. Transplan-
tation. 2002;74:123-7. 
Rayes N, Seehofer D, Theruvath T, Schiller RA, 
Langrehr JM, Jonas S, et al. Supply of pre- and probi-
otics reduces bacterial infection rates after liver trans-
plantation--a randomized, double-blind trial. Am J 
Transplant. 2005;5:125-30. 
Reid G, Dols J, Miller W. Targeting the vaginal micro-
biota with probiotics as a means to counteract infec-
tions. Curr Opin Clin Nutr Metab Care. 2009;12:583-
7. 
Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes 
J. Reticuloendothelial system phagocytic activity in 
cirrhosis and its relation to bacterial infections and 
prognosis. Hepatology. 1984;4:53-8. 
EXCLI Journal 2017;16:278-290 – ISSN 1611-2156 
Received: December 18, 2016, accepted: February 11, 2017, published: March 20, 2017 
 
 
290 
Rodrigo R, Prat H, Passalacqua W, Araya J, Bachler 
JP. Decrease in oxidative stress through supplementa-
tion of vitamins C and E is associated with a reduction 
in blood pressure in patients with essential hyperten-
sion. Clin Sci. 2008;114:625-34. 
Sawada H, Furushiro M, Hirai K, Motoike M, 
Watanabe T, Yokokura T. Purification and characteri-
zation of an antihypertensive compound from Lactoba-
cillus casei. Agric Biol Chem. 1990;54:3211-9. 
Solga SF, Diehl AM. Non-alcoholic fatty liver disease: 
lumen-liver interactions and possible role for probiot-
ics. J Hepatol. 2003;38:681-7. 
Tandon P, Moncrief K, Madsen K, Arrieta MC, Owen 
RJ, Bain VG, et al. Effects of probiotic therapy on por-
tal pressure in patients with cirrhosis: a pilot study. 
Liver Int. 2009;29:1110-5. 
Tatsch E, Bochi GV, Pereira Rda S, Kober H, Agertt 
VA, de Campos MM, et al. A simple and inexpensive 
automated technique for measurement of serum ni-
trite/nitrate. Clin Biochem. 2011;44:348-50. 
Tilg H, Diehl AM. Cytokines in alcoholic and nonal-
coholic steatohepatitis. N Engl J Med. 2000;343:1467-
76. 
Vajro P, Mandato C, Franzese A, Ciccimarra E, Lu-
cariello S, Savoia M, et al. Vitamin E treatment in pe-
diatric obesity-related liver disease: a randomized 
study. J Pediatr Gastroenterol Nutr. 2004;38:48-55. 
Vajro P, Mandato C, Licenziati MR, Franzese A, Vi-
tale DF, Lenta S, et al. Effects of Lactobacillus rham-
nosus strain GG in pediatric obesity-related liver dis-
ease. J Pediatr Gastroenterol Nutr. 2011;52:740-3. 
van Baarlen P, Troost F, van der Meer C, Hooiveld G, 
Boekschoten M, Brummer RJ, et al. Human mucosal in 
vivo transcriptome responses to three lactobacilli indi-
cate how probiotics may modulate human cellular 
pathways. Proc Natl Acad Sci U S A. 2011;108(Suppl 
1):4562-9. 
Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol 
EJ. Use of antioxidant vitamins for the prevention of 
cardiovascular disease: meta-analysis of randomised 
trials. Lancet. 2003;361(9374):2017-23. 
Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien 
S, Groszmann RJ. Bacterial translocation in cirrhotic 
rats stimulates eNOS-derived NO production and im-
pairs mesenteric vascular contractility. J Clin Invest. 
1999;104:1223-33. 
Wilkinson IB, Franklin SS, Cockcroft JR. Nitric oxide 
and the regulation of large artery stiffness: from phys-
iology to pharmacology. Hypertension. 2004;44:112-
6. 
Wong VW, Wong GL, Yeung DK, Abrigo JM, Kong 
AP, Chan RS, et al. Fatty pancreas, insulin resistance, 
and beta-cell function: a population study using fat-wa-
ter magnetic resonance imaging. Am J Gastroenterol. 
2014;109:589-97. 
Yamamoto N, Akino A, Takano T. Antihypertensive 
effect of the peptides derived from casein by an extra-
cellular proteinase from Lactobacillus helveticus 
CP790. J Dairy Sci. 1994;77:917-22. 
Zhang Y, Du R, Wang L, Zhang H. The antioxidative 
effects of probiotic Lactobacillus casei Zhang on the 
hyperlipidemic rats. Eur Food Res Technol. 2010;231: 
151-8. 
